Abstract
Crohn's disease and ulcerative colitis are idiopathic inflammatory bowel diseases characterized by dysregulated intestinal immune responses in genetically susceptible hosts. Conventional approaches to the medical therapy of ulcerative colitis and Crohn's disease can now be directed at either induction or maintenance of remission to improve therapeutic efficacy while minimizing complications. Newer approaches have expanded the utility of conventional therapies by improving both safety and efficacy and highlight the importance of specific targets along the immunoinflammatory pathways. The combination of conventional and novel approaches now offers the potential of modifying the natural history of these diseases.
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Inflammatory Agents / pharmacology
-
Anti-Inflammatory Agents / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Azathioprine / pharmacology
-
Azathioprine / therapeutic use
-
Cyclosporins / pharmacology
-
Cyclosporins / therapeutic use
-
Humans
-
Immunosuppressive Agents / pharmacology
-
Immunosuppressive Agents / therapeutic use
-
Inflammatory Bowel Diseases / drug therapy*
-
Inflammatory Bowel Diseases / etiology
-
Inflammatory Bowel Diseases / immunology
-
Mesalamine / pharmacology
-
Mesalamine / therapeutic use
-
Methotrexate / pharmacology
-
Methotrexate / therapeutic use
-
Mycophenolic Acid / analogs & derivatives*
-
Mycophenolic Acid / pharmacology
-
Mycophenolic Acid / therapeutic use
-
Steroids
-
Tacrolimus / pharmacology
-
Tacrolimus / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Anti-Inflammatory Agents
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cyclosporins
-
Immunosuppressive Agents
-
Steroids
-
Mesalamine
-
Mycophenolic Acid
-
Azathioprine
-
Tacrolimus
-
Methotrexate